Evidence map›Paper›PMID 38962412›Full record

ArticleNagoya journal of medical science2024

Risk factors for nausea and vomiting requiring the daily administration of 5-HT

Mai Takagi, Atsunobu Sagara, Yasuo Kumakura, Minako Watanabe, Rikako Inoue, Masayuki Miyazaki, Fumiharu Ohka, Kazuya Motomura, Atsushi Natsume, Toshihiko Wakabayashi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nagoya journal of medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mai TakagiDepartment of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Japan.
Atsunobu SagaraDepartment of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Japan.
Yasuo KumakuraDepartment of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Japan.
Minako WatanabeDepartment of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Japan.
Rikako InoueDepartment of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Japan.
Masayuki MiyazakiDepartment of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Japan.
Fumiharu OhkaDepartment of Neurosurgery, Nagoya University Hospital, Nagoya, Japan.
Kazuya MotomuraDepartment of Neurosurgery, Nagoya University Hospital, Nagoya, Japan.
Atsushi NatsumeDepartment of Neurosurgery, Nagoya University Hospital, Nagoya, Japan.
Toshihiko WakabayashiDepartment of Neurosurgery, Nagoya University Hospital, Nagoya, Japan.
Ryuta SaitoDepartment of Neurosurgery, Nagoya University Hospital, Nagoya, Japan.
Kiyofumi YamadaDepartment of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy combined with temozolomide (TMZ+RT) is the primary treatment for high-grade glioma. TMZ is classified as a moderate emetic risk agent and, thus, supportive care for nausea and vomiting is important. In Nagoya University Hospital, all patients are treated with a 5-hydroxy-tryptamine 3 receptor antagonist (5-HT

Indexed as

GliomaNauseaSerotonin 5-HT3 Receptor AntagonistsTemozolomideVomitingAdultAgedAntineoplastic Agents, AlkylatingBrain NeoplasmsChemoradiotherapyFemaleHumansMaleMiddle AgedRisk FactorsAntineoplastic Agents, AlkylatingSerotonin 5-HT3 Receptor AntagonistsTemozolomide5-hydroxy-tryptamine 3 receptor antagonistantiemeticgliomanausea and vomitingtemozolomide

Identifiers

PMID38962412
PMCPMC11219229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.